174 related articles for article (PubMed ID: 14577491)
21. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.
Friedrich MG; Blind C; Milde-Langosch K; Erbersdobler A; Conrad S; Löning T; Hammerer P; Huland H
Eur Urol; 2001 Nov; 40(5):518-24. PubMed ID: 11752859
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
[TBL] [Abstract][Full Text] [Related]
23. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
Sun W; Zhang PL; Herrera GA
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
[TBL] [Abstract][Full Text] [Related]
24. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
[TBL] [Abstract][Full Text] [Related]
26. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
[TBL] [Abstract][Full Text] [Related]
27. p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder.
Asci R; Yildiz L; Sarikaya S; Buyukalpelli R; Yilmaz AF; Kandemir B
Urol Int; 2001; 67(1):34-40. PubMed ID: 11464113
[TBL] [Abstract][Full Text] [Related]
28. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
29. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
[TBL] [Abstract][Full Text] [Related]
30. Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2.
Sakr SA; Mahran HA; Fahmy AM; El-Kholy MA; Meawad M
Biomed Pharmacother; 2015 Dec; 76():73-81. PubMed ID: 26653553
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.
Vet JA; Witjes JA; Marras SA; Hessels D; van der Poel HG; Debruyne FM; Schalken JA
Clin Cancer Res; 1996 Jun; 2(6):1055-61. PubMed ID: 9816267
[TBL] [Abstract][Full Text] [Related]
32. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
[TBL] [Abstract][Full Text] [Related]
33. p53 gene mutation in recurrent superficial bladder cancer.
Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical detection of p53 protein in transitional cell carcinoma of the bladder in correlation to DNA ploidy and pathohistological stage and grade.
al-Abadi H; Nagel R; Neuhaus P
Cancer Detect Prev; 1998; 22(1):43-50. PubMed ID: 9466048
[TBL] [Abstract][Full Text] [Related]
35. [The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer].
Soukup V; Babjuk M; Dusková J; Pesl M; Szakácsova M; Zámefnik L; Dvorácek J
Cas Lek Cesk; 2007; 146(1):63-7. PubMed ID: 17310587
[TBL] [Abstract][Full Text] [Related]
36. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder.
Hinz S; Kempkensteffen C; Weikert S; Schostak M; Schrader M; Miller K; Christoph F
Tumour Biol; 2007; 28(3):151-7. PubMed ID: 17541304
[TBL] [Abstract][Full Text] [Related]
37. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
38. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
39. [The study of p53 gene mutation in human bladder cancer].
Ding Q; Zhang Y; Sun X
Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
[TBL] [Abstract][Full Text] [Related]
40. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
